Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme - Wikidata - wikimedia - TriplyDB

Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme

Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme

http://www.wikidata.org/entity/Q24805211

about

Whole-body biodistribution kinetics, metabolism, and radiation dosimetry estimates of 18F-PEG6-IPQA in nonhuman primates Reference Data for Standardized Quality of Life Questionnaires in Indian Patients with Brain Metastases from Non-small Cell Lung Cancer: Results from a Prospective Study.Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT Gefitinib: an adverse effects profile.A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer.Health-related quality of life questionnaires in lung cancer trials: a systematic literature review Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies.Identification of ATP synthase beta subunit (ATPB) on the cell surface as a non-small cell lung cancer (NSCLC) associated antigen Gefitinib in the treatment of advanced non-small-cell lung cancer.Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review.Use of the lung cancer-specific Quality of Life Questionnaire EORTC QLQ-LC13 in clinical trials: A systematic review of the literature 20 years after its development.

P2860

Q33579133-3F66934D-A6CD-484F-B83D-C168AC31AEC4 Q33658254-2135CAC2-139A-44BA-AFBD-EBA21EB1279D Q34534164-A615A39B-8918-4B48-8677-8E80A7020899 Q36446915-E0FB4F3C-F383-4C73-A9A5-5C9B846B505B Q36614353-20C87DD9-D253-4158-9CDD-2BEE6258F323 Q36884830-35F0C28B-FC98-4106-B930-9B615E5085B4 Q36966043-12E50796-143E-40EF-85B0-15EB0050C899 Q37125361-CBEA19D2-A854-4E4D-8A38-33D08F2911D7 Q37449013-9C1FAF3B-7478-4FD3-A4F2-85B8ACC60E17 Q37579644-A9195C51-B3C7-48A8-9ADF-4425294D0D75 Q38027080-6F803639-C556-439C-9E1E-D61C9EF035D7 Q38602994-58DB3A32-0DE0-4A9E-89C9-77F7739CDC66

P2860

Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme

http://www.wikidata.org/entity/Q24805211

description

2004 nî lūn-bûn

@nan

2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Evaluation of safety and effic ...... a compassionate-use programme

@ast

Evaluation of safety and effic ...... a compassionate-use programme

@en

Evaluation of safety and effic ...... a compassionate-use programme

@nl

type

label

Evaluation of safety and effic ...... a compassionate-use programme

@ast

Evaluation of safety and effic ...... a compassionate-use programme

@en

Evaluation of safety and effic ...... a compassionate-use programme

@nl

prefLabel

Evaluation of safety and effic ...... a compassionate-use programme

@ast

Evaluation of safety and effic ...... a compassionate-use programme

@en

Evaluation of safety and effic ...... a compassionate-use programme

@nl

P1433

Q24805211-2DF8E61B-9A57-4DA4-A0F5-FE0F8FFD8B63

P1476

Q24805211-D39114D4-DC8B-46DB-BB7B-2FDE2099C64C

P2093

Q24805211-28AE1D53-AFE1-4C55-BAAB-6008526A76DA

Q24805211-65CFA34D-F528-483F-B520-56CEF934609B

Q24805211-7C940D3B-2C0C-4E52-87AA-99E7F61F16D7

Q24805211-AD51A7C7-3433-4D73-8BB6-FA9C305EC68F

Q24805211-B103448A-0809-405D-9FB3-7E8BFD6C98C7

P2860

Q24805211-06B5C02C-3469-4107-A342-B067F4199CAB

Q24805211-165EA44F-622B-47C3-9464-DD2F95E5FD41

Q24805211-338C41EB-84FD-4216-9A9E-0514A0FD333C

Q24805211-34DA2865-0B28-4592-BD84-22ADCCBB7973

Q24805211-377AE101-1DB4-477C-BF8B-099A5DA0D4EA

Q24805211-471D2A6C-C311-4F9F-B368-555831468DB3

Q24805211-4F60AA12-88D5-4386-AE71-3212F43A691B

Q24805211-53BC7BFD-BF6D-4274-B9CD-607C1A685BA5

Q24805211-9837CC69-E337-4455-8274-8A011DBDF78F

Q24805211-B16AE15F-016C-4699-B6FC-8F5D4BA9099F

P2888

Q24805211-474452F7-9836-4B13-9CF8-5FC256E25CA2

P304

Q24805211-FFE12AD2-34E4-4CDF-BF92-4198809B24A8

P31

Q24805211-B56A1A96-90A1-472C-A106-040187973C47

P356

Q24805211-AC6B51FF-3055-4D66-AC93-DA08B757FCD7

P407

Q24805211-8670C361-D9C3-4BAF-BD97-5838E0CB7630

P433

Q24805211-78A38B54-E20E-4052-B19D-24D5BDE8F72B

P478

Q24805211-2A5BF36E-DEB2-447D-87C3-36F04263A318

P577

Q24805211-AD362BAC-6F58-41D0-8882-98C1EB198001

P5875

Q24805211-FDFF4B9A-1326-4FD4-992A-5007731F9609

P6179

Q24805211-9A6CECF7-7A11-4E16-A5C6-A5568064C80E

P698

Q24805211-8BE4B6AC-AC7C-4163-B751-F6E844E016E9

P932

Q24805211-C8BB198D-E9FC-4D98-8288-200A20DAF227

P356

P1433

P1476

Evaluation of safety and effic ...... a compassionate-use programme

@en

P2093

Long-Yun Li

http://www.w3.org/2001/XMLSchema#string

Meng-Zhao Wang

http://www.w3.org/2001/XMLSchema#string

Shu-Lan Wang

http://www.w3.org/2001/XMLSchema#string

Xiao-Tong Zhang

http://www.w3.org/2001/XMLSchema#string

Xin-Lin Mu

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer.

Translation and validation of the standard Chinese version of the EORTC QLQ-C30.

The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents.

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies.

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.

Expression of epidermal growth factor receptor (EGF-R) in human lung tumours.

P2888

P304

51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-4-51

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2004-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8392544

http://www.w3.org/2001/XMLSchema#string

P6179

1022804826

http://www.w3.org/2001/XMLSchema#string

P698

15318946

http://www.w3.org/2001/XMLSchema#string

P932

516034

http://www.w3.org/2001/XMLSchema#string